Bionano genomics news.
We believe this technology-centric view is holding us back from the answers to critical questions around the origin, diagnosis, severity and treatment of cancer and genetic disease. We believe the way to move forward is an inclusive one that reveals what other tools miss and unifies data across technologies into one view to maximize the ...
A-smart is Bionano’s second Chinese OEM partner to obtain approval from NMPA for the Company’s optical genome mapping (OGM) solutions. NMPA issued two approvals to A-smart: one for Bionano’s G2 direct label and stain (DLS) DNA labeling kit and one for Bionano’s G2 SP bone marrow aspirate (BMA) DNA isolation kit.Q2 2023 revenue was $8.7 million , which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023 , which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023 , which represents a 108% increase over theSAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano’s optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories’ first OGM-based laboratory developed test (LDT).News Release Details « Back. Bionano Strategy Day Highlighted the Company’s Strategic Initiatives and Growth Plans as well as OGM’s Competitive Value for Cell Bioprocessing, and Cancer and Genetic Disease Research. ... -- Bionano Genomics, Inc. (BNGO) today announced details of topics covered at the company’s first-ever …Bionano Genomics, Inc. (NASDAQ:NASDAQ:BNGO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ETCompany ParticipantsAmy Conrad - Investor RelationsErik Holmlin - Chief Executive...
Jan 12, 2023 · About Bionano Genomics, Inc. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from researchers...Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.11 per share a year ago.
Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.11 per share a year ago.Bionano Genomics' $2.1 million in cash in SVB accounts is part of $113.2 million in cash, cash equivalents and AFS securities. MarketWatch Mar 13, 2023 7:41am.Nov 29, 2023 · SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural variations (SVs) introduced by CRISPR-Cas9 gene editing of CD4+ T-cells that could potentially limit the therapeutic use of such edited cells. News Release Details « Back. Bionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies. Feb 22, 2023 | PDF Version. ... About Bionano Genomics. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers …News Release Details « Back. Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results. Jan 05, 2023 | PDF Version - Preliminary Q4 revenue expected to be between $8.1 and $8.4 million; 29% to 33% increase over Q4 2021 - Reached installed base of 240 systems as of YE 2022; 46% increase over YE 2021 ...
Apr 13, 2023 · The current analyst consensus has Bionano Genomics, Inc. losing around 45 cents a share in FY2023 as sales rise nearly 30% to $35.7 million. Revenue growth is projected to accelerate by over 70% ...
The market expects Bionano Genomics, Inc. (BNGO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2022.
News Release Details « Back. Bionano Genomics Reports Second Quarter 2022 Financial Results and Highlights Recent Business Progress. Aug 04, 2022 | PDF …Stock Performance. Shares of Bionano Genomics were trading at $1.63 as of November 06. Over the last 52-week period, shares are down 92.9%. Given that these returns are generally negative, long ...NEW YORK – Bionano Genomics said on Friday afternoon that the company is executing a 1-for-10 reverse stock split of its issued and outstanding common stock. The move will take effect at 5 p.m. Eastern Daylight Time on August 4, and the company's common stock will begin trading on a split-adjusted basis commencing upon market …SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families. The study authors conducted a comprehensive analysis of samples from ...Q2 2023 revenue was $8.7 million , which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023 , which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023 , which represents a 108% increase over the
Bionano announced today that it has priced a financing to raise an aggregate of $80.0 million in a registered offering and concurrent private placement of senior secured convertible notes due 2025... SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million …SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, a...Get the latest BioNano Genomics Inc (BNGO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Company profile page for Bionano Genomics Inc including stock price, company news, executives, board members, and contact information.Bionano Genomics Expects $80 Million in Gross Proceeds From Registered Offering, Private Placement. Oct. 11. MT. Bionano Genomics, Inc. Revises Revenue Guidance for the Third Quarter Ended September 30, 2023. Oct. 11. CI. Bionano Genomics, Inc. announced that it expects to receive $35 million in funding. Oct. 10.
Bionano Genomics: PB2245: A combination of exome sequencing and optical genome mapping unveils a dual molecular diagnosis in a case with an unknown neurodevelopmental disorder Acharya A. Columbia University: PB2261: B-allele frequency-based approach to detecting absence of heterozygosity using optical genome mapping …
Genetic information is stored in several places, which are DNA molecules, genes, chromosomes, mitochondria and the genome. Different amounts and types of genetic information are stored in these locations.Over the past 30 days, the shares of Bionano Genomics Inc (NASDAQ:BNGO) have changed 24.81%. Short interest in the company has seen 7.08 million shares shorted with days to cover at 6.06. Wall Street analysts have a consensus price target for the stock at $12.33, which means that the shares’ value could jump 86.54% from current levels.9 Mar 2023 ... News Release Details. « Back. Bionano Genomics Reports Fourth Quarter and Full-Year 2022 Results and Provides Revenue Outlook for 2023. Mar 09 ...SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2023. Business Updates Since the End ...Sep 28, 2023 · SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders, chromosomal microarray analysis (CMA). SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural variations (SVs) introduced by CRISPR-Cas9 gene editing of CD4+ T-cells that could potentially limit the therapeutic use of such edited cells.. The …Oct 10, 2023 · NEW YORK – Bionano Genomics this week executed a new round of layoffs, GenomeWeb has learned. According to information obtained by GenomeWeb from former employees who wished to remain anonymous, the workforce reduction appears to impact around 60 employees, although company executives declined to comment. By Robert Lakin, InvestorPlace Contributor Jun 7, 2021, 9:34 am EST. Investors in Bionano Genomics (NASDAQ: BNGO) Monday morning are picking up where they left off on Friday, boosting the shares ...SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic ...SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that its Chinese OEM partner, Ecobono, a distribution …
BNGO Stock 12 Months Forecast. $6.33. (298.11% Upside) Based on 3 Wall Street analysts offering 12 month price targets for BioNano Genomics in the last 3 months. The average price target is $6.33 with a high forecast of $7.00 and a low forecast of $6.00. The average price target represents a 298.11% change from the last price of $1.59.
– Acquisition of BioDiscove ry transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics – Total revenue of $4.7 million , a 112% year-over-year total revenue increase, driven by
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today.The final voting results will be available in a current report on Form 8-K, which will be filed with the SEC within 4 days of the meeting. “We appreciate …Mar 7, 2023 · Bionano Genomics. Market Cap. $61M. Today's Change. (4.64%) $0.07. Current Price. $1.58. Price as of November 29, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may differ ... Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing ...Fiscal Q3 2023 ended 9/30/23. Reported on 11/8/23. Get the latest BioNano Genomics Inc (BNGO) real-time quote, historical performance, charts, and other financial information to …Aug 14, 2023 · A big change in the C-suite was behind the steep fall in Bionano Genomics ' ( BNGO -7.27%) share price on Monday. Following the biotech's announcement that its CFO is stepping down, investors ... Mar 31, 2022 · SAN DIEGEO, May 05, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of NxClinical™ software, a leading solution for visualization, interpretation and reporting of genomic data, today reported financial results for the first quarter ended ... An Accounting Trick Not to Neglect. Shareholders of Bionano Genomics have been diluted in the past year, with total shares outstanding growing by 6.4%.. This is the base news for valuation ...SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.
Bionano Genomics News: This is the News-site for the company Bionano Genomics on Markets Insider Indices Commodities Currencies StocksFind real-time BNGO - Bionano Genomics Inc stock quotes, company profile, ... No recent news for Bionano Genomics Inc. Today’s Trading. Previous close: 1.59: Today’s open: 1.55:The current analyst consensus has Bionano Genomics, Inc. losing around 45 cents a share in FY2023 as sales rise nearly 30% to $35.7 million. Revenue growth is projected to accelerate by over 70% ...Instagram:https://instagram. best jewlery insurancebest forex broker reviewbest forex trading brokerswwe stck Bionano Genomics Q3 Revenues Grow 29 Percent. In line with its previous estimate, the San Diego-based optical genome mapping company reported $9.3 million in revenues, compared to $7.2 million a year ago. liberanday trading sim Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today.The final voting results will be available in a current report on Form 8-K, which will be filed with the SEC within 4 days of the meeting. “We appreciate … vanguard mid cap etf SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant progress in China with the adoption of its Saphyr® System …Jun 14, 2023 · Bionano Announces Results from its Annual Meeting of Stockholders. SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today. The final voting results will be available in a current report on Form 8-K, which ...